Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.61 |
| ▸ | APP | P05067 | 2/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CCR6 | P51684 | 1/20 | 0.45 |
| ▸ | UBE2N | P61088 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10991891 | 0.85 | MAOB (0.80) | MAOBAPPNR4A2MAOADHFR | |
| SCHEMBL7253638 | 0.82 | IDO1 (0.45) | MAOBAPPNR4A2MAOAIDO1 | |
| SCHEMBL6544765 | 0.82 | APP (0.60) | APPIDO1BCHELMNAKDM4E | |
| SCHEMBL832412 | 0.81 | GPR84 (0.50) | MAOBAPPMAOANPC1RAB9A | |
| SCHEMBL27553486 | 0.80 | MAOB (0.61) | MAOBAPPMAOARAB9A | |
| SCHEMBL1283621 | 0.80 | APP (0.61) | MAOBAPPMAOAIDO1 | |
| SCHEMBL1282632 | 0.80 | LMNA (0.62) | MAOBAPPNR4A2MAOABCHE | |
| SCHEMBL697362 | 0.80 | MAOB (0.61) | MAOBAPPNR4A2MAOAIDO1 | |
| SCHEMBL543113 | 0.80 | MAOB (0.54) | MAOBAPPMAOAAGXTLMNA | |
| SCHEMBL696583 | 0.79 | IDO1 (0.52) | MAOBMAOAIDO1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108409837-B | Glycopeptide compound with anti-drug resistance bacterial activity, preparation method and application thereof | 上海来益生物药物研究开发中心有限责任公司 | 2021-09-24 | — | — | CN | claimed |
| WO-2019170046-A1 | GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海来益生物药物研究开发中心有限责任公司 | 2019-09-12 | — | — | WO | claimed |
| WO-2014186325-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING INDOLE PHARMACEUTICALS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2014-11-20 | — | — | WO | claimed |
| US-8362000-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-29 | — | — | US | claimed |
| EP-2421847-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-20 | — | — | US | claimed |
| WO-2010124116-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| CN-100469788-C | Glycopeptide phosphonate derivatives | ADVANCED MEDICINE INC (US) | 2009-03-18 | — | — | CN | claimed |
| CN-108409837-B | Glycopeptide compound with anti-drug resistance bacterial activity, preparation method and application thereof | 上海来益生物药物研究开发中心有限责任公司 | 2021-09-24 | — | — | CN | disclosed |
| WO-2019170046-A1 | GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海来益生物药物研究开发中心有限责任公司 | 2019-09-12 | — | — | WO | disclosed |
| US-9751835-B2 | Processes and intermediates for preparing indole pharmaceuticals | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-09-05 | — | — | US | disclosed |
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| EP-2865670-B1 | Thiourea derivatives as glutaminyl cyclase inhibitors | PROBIODRUG AG (DE) | 2017-01-11 | — | — | EP | disclosed |
| US-9512082-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-12-06 | — | — | US | disclosed |
| EP-0165209-A2 | o,p-Bifunctionalised, o'-substituted phenols | CIBA-GEIGY AG (CH) | 1985-12-18 | — | — | EP | disclosed |
| EP-0007347-B1 | ALKYLENGLYCOL COMPOUNDS FOR LOWERING THE LIPID CONTENT AND PROCESSES FOR THE PREPARATION THEREOF | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1981-12-30 | — | — | EP | disclosed |
| US-4275068-A | (BENZYLPHENOXY)-ALKANOLS AS ANTICHOLESTEROL AND ANTILIPEMIC AGENTS | SIEGFRIED AG (CH) | 1981-06-23 | — | — | US | disclosed |
| US-4198205-A | SULFONIC ACID-FREE DISPERSE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1980-04-15 | — | — | US | disclosed |
| EP-0007347-A1 | Alkylenglycol compounds for lowering the lipid content and processes for the preparation thereof. | SIEGFRIED AG (CH) | 1980-02-06 | — | — | EP | disclosed |
| WO-1979000116-A1 | NEW GLYCOL COMPOUNDS FOR LOWERING THE LIPID CONTENT | SIEGFRIED AG (CH) | 1979-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015171-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | MAOB 428/4885APP 3490/4885NR4A2 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.